New Peer-Reviewed MEBO COVID-19 study

Although systemic malodor is commonly overlooked by physicians, it constitutes a major problem for many otherwise healthy people. Yet, this condition has thus far eluded effective treatments or cures in many individuals. The number of potentially responsible SNPs, genes, microbes and related disorders is large and keeps increasing, overlapping with confounders of COVID-19.  

Decentralized observational study NCT04832932 compared MEBO participants to general populations in respect to their response to COVID-19 vaccines and SARS-Co-V2 infections. 

Body odor flareups were observed in about 10% of current or former malodor sufferers after vaccination, as preliminarily reported. This number was similar to flareups of other chronic symptoms in groups of participants with gastrointestinal and autoimmune disorders.  

Long-term worsening of body odor was observed by other researchers after COVID-19 vaccination in about ~1% of studied populations. Dry mouth leading to halitosis was 10 times more prevalent compared to flu vaccines. MEBO participants reported stronger reactions than general population pointing to genetic and microbiome influences beyond FMO3.  

A better understanding of systemic malodor conditions could offer leads for targeted therapies. Findings on genetic and microbiome overlaps between COVID-19 and MEBO could pave the way for precision medicine to address the unmet needs of odor sufferers.

REFERENCE 

Gabashvili IS. The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups. JMIR Formative Research. 2022 Nov;6(11):e41914. DOI: 10.2196/41914. PMID: 36309347; PMCID: PMC9640199.

get New Posts by EMAIL : Enter your email address :

---

A EURORDIS and NORD Member Organization